Shionogi Secures BARDA Funding for Long-Acting COVID-19 Antiviral Development

The latest announcement is out from Shionogi & Co ( (JP:4507) ).

Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development Authority (BARDA) to develop S-892216, a long-acting injectable antiviral for COVID-19 pre-exposure prophylaxis. This development aims to fill a gap in pre-exposure prophylaxis therapeutics, with plans to start phase 1 studies in the U.S. in 2025. The initiative underscores Shionogi’s continued efforts to combat COVID-19, complementing its ongoing development of other antiviral treatments and its commitment to global health security.

More about Shionogi & Co

Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, known for its focus on the development of therapeutics, particularly in the infectious disease sector. The company is dedicated to advancing public health by developing products and services that address pandemics, with a commitment to equitable access across global markets including low- and middle-income countries.

YTD Price Performance: 15.35%

Average Trading Volume: 513

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $12.71B

For an in-depth examination of 4507 stock, go to TipRanks’ Stock Analysis page.